WuXi AppTec (603259) Stock Overview
An investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
603259 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
CN¥124.31
FV
0.2% overvalued intrinsic discount15.66%
Revenue growth p.a.
60
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
WuXi AppTec Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥124.51 |
| 52 Week High | CN¥126.80 |
| 52 Week Low | CN¥68.90 |
| Beta | 0.49 |
| 1 Month Change | 22.55% |
| 3 Month Change | 19.94% |
| 1 Year Change | 76.11% |
| 3 Year Change | 92.00% |
| 5 Year Change | -14.74% |
| Change since IPO | 841.63% |
Recent News & Updates
Narrative Update • Jun 29
603259: APAC Conviction List Inclusion Will Support Upside From Ongoing Share Buybacks
Analysts have raised their fair value estimate for WuXi AppTec from CN¥137.83 to CN¥145.96, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that are reflected in recent research, including its addition to a major APAC conviction list. What's in the News for WuXi AppTec WuXi AppTec's Board of Directors authorized a new share buyback plan on June 9, 2026, signaling continued use of repurchases as a capital management tool.
Narrative Update • Jun 15
603259: Conviction List Addition Will Support Confidence In 2026 Buyback Plan
Analysts have maintained their CN¥124.40 price target for WuXi AppTec, keeping it broadly in line with previous estimates. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions, as well as its recent addition to a major APAC conviction list by Street research.
Narrative Update • Jun 01
603259: Conviction List Inclusion And Buybacks Are Expected To Support Future Earnings
Analysts have raised their price target for WuXi AppTec from CN¥152.00 to about CN¥169.13, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. This shift aligns with recent positive Street research attention, including the stock being added to a major APAC conviction list.Recent updates
Narrative Update • Jun 29
603259: APAC Conviction List Inclusion Will Support Upside From Ongoing Share Buybacks
Analysts have raised their fair value estimate for WuXi AppTec from CN¥137.83 to CN¥145.96, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E that are reflected in recent research, including its addition to a major APAC conviction list. What's in the News for WuXi AppTec WuXi AppTec's Board of Directors authorized a new share buyback plan on June 9, 2026, signaling continued use of repurchases as a capital management tool.Narrative Update • Jun 15
603259: Conviction List Addition Will Support Confidence In 2026 Buyback Plan
Analysts have maintained their CN¥124.40 price target for WuXi AppTec, keeping it broadly in line with previous estimates. This reflects updated views on discount rates, revenue growth, profit margins and future P/E assumptions, as well as its recent addition to a major APAC conviction list by Street research.Narrative Update • Jun 01
603259: Conviction List Inclusion And Buybacks Are Expected To Support Future Earnings
Analysts have raised their price target for WuXi AppTec from CN¥152.00 to about CN¥169.13, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. This shift aligns with recent positive Street research attention, including the stock being added to a major APAC conviction list.Narrative Update • May 18
603259: Conviction List Inclusion Will Support Confidence In 2026 Guidance
Analysts have lifted their price target on WuXi AppTec to CN¥124.40, supported by a lower discount rate, slightly adjusted growth and margin assumptions, and a reduced future P/E multiple that still keeps the stock on key conviction lists. Analyst Commentary Recent commentary on WuXi AppTec sits against the backdrop of a refreshed price target of CN¥124.40, with major firms such as Goldman Sachs keeping the stock on key conviction lists, even as some investors weigh execution and valuation risks.
New Narrative • May 02
Why is WuXi AppTec a company of the future?
WuXi AppTec (603259.SH / 2359.HK) — this is not just a pharmaceutical company; it is the "infrastructure foundation" of the global bio-industry. It operates under the CRDMO (Contract Research, Development, and Manufacturing Organization) model, providing services from molecule discovery to mass production of drugs.Narrative Update • Apr 28
603259: APAC Conviction List Inclusion Will Support Long Term Upside
Analysts have lifted their CN¥ price target for WuXi AppTec from about CN¥129.89 to around CN¥137.83, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E in light of recent positive research attention, including the stock's addition to a major APAC conviction list and a fresh upgrade. Analyst Commentary Bullish Takeaways Bullish analysts point to the stock's addition to a major APAC conviction list as a sign of increased confidence in WuXi AppTec's ability to execute on its business plans and support the updated valuation assumptions.Narrative Update • Apr 14
603259: Conviction List Inclusion And 2026 Guidance Will Shape Balanced Outlook
Analysts have adjusted their price target on WuXi AppTec to CN¥114.80 from CN¥123.00, reflecting updated views on revenue growth, profit margins, and a lower future P/E multiple following recent upgrades and the stock’s addition to an APAC conviction list. Analyst Commentary Recent research around WuXi AppTec highlights a mix of optimism and caution.Narrative Update • Mar 31
603259: Higher Margins And New Guidance Are Expected To Support Future Earnings
Analysts have lifted their price target on WuXi AppTec to CN¥152.00 from CN¥145.50, citing updated assumptions on revenue growth, profit margins and a slightly adjusted discount rate, alongside higher expected future P/E levels. Analyst Commentary Recent research points to a clearly supportive stance on WuXi AppTec, with bullish analysts highlighting updated assumptions on revenue, margins and valuation multiples as the main drivers behind higher price targets.Narrative Update • Mar 17
603259: Lower Discount Rate And Margin Outlook Will Support Future Earnings Power
Analysts see scope for WuXi AppTec's CN¥145.50 price target to be supported by a slightly lower discount rate, a higher projected profit margin and a modestly lower future P/E, with recent research upgrades reinforcing this updated view. Analyst Commentary Recent Street research around WuXi AppTec has leaned more constructive, with at least one major upgrade and a closer alignment between the current share price and the CN¥145.50 price target.Narrative Update • Mar 03
603259: Execution On Upgraded Outlook And 2025 Guidance Will Drive Upside
The latest analyst price target for WuXi AppTec has been revised to CN¥123.00. Analysts highlight updated assumptions on revenue growth, profit margins and future P/E, along with recent supportive Street research, as the key factors behind this change.Narrative Update • Feb 16
603259: Upgraded Outlook Will Rely On Execution To Unlock Upside
Analysts have lifted their price target on WuXi AppTec from CN¥89.70 to CN¥123.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins and future P/E following recent Street research. Analyst Commentary While some research, including a recent upgrade from Goldman Sachs, points to upside based on revised assumptions, there is still a group of bearish analysts highlighting risks that could limit how much of that upside is realized.Narrative Update • Feb 02
603259: Higher 2025 Earnings Guidance Will Support Future Earnings Power
Analysts have lifted their fair value estimate for WuXi AppTec from $142.00 to $145.50, citing updated assumptions around revenue growth, profit margins and the future P/E multiple. What's in the News WuXi AppTec issued earnings guidance for full year 2025, with total revenue expected at approximately RMB 45.46b.Narrative Update • Jan 19
603259: Saudi Partnerships And 2025 Earnings Guidance Will Support Long Term Upside
Analysts have nudged their price target on WuXi AppTec higher to reflect updated fair value estimates of about US$129.89, supported by slightly adjusted assumptions for revenue growth, profit margins, discount rate and future P/E multiples. What's in the News WuXi AppTec issued earnings guidance for full year 2025, with total revenue expected at about RMB 45.46b and revenue from Continuing Operations described as growing by about 21.4% year over year (Corporate Guidance).Narrative Update • Jan 05
603259: Saudi Partnerships And Localized Production Will Support Earnings Power
Analysts have maintained their fair value estimate for WuXi AppTec at $142.00, making only small adjustments to their assumptions. These include a slightly higher discount rate, a marginally higher revenue growth outlook, a modestly lower profit margin, and a similar forward P/E multiple.Narrative Update • Dec 21
603259: Saudi Expansion Will Support Higher Margins And Earnings Power
Analysts have raised their fair value estimate for WuXi AppTec by around 3 dollars to approximately 142 dollars, citing a more favorable profit margin outlook and a lower assumed future price to earnings multiple. Together, these factors more than offset slightly softer revenue growth assumptions and a modestly higher discount rate.Narrative Update • Dec 07
603259: Saudi Partnerships Will Drive Long Term Earnings Power
Analysts have nudged their price target on WuXi AppTec slightly higher to approximately $126 per share, reflecting modestly stronger assumptions for long term revenue growth and profit margins, supported by the company’s resilient business model and improving operating efficiency. What's in the News Signed two strategic MoUs with NEOM and Saudi Arabia's Ministry of Health to localize pharmaceutical R&D, manufacturing, and workforce development in the Kingdom, positioning WuXi AppTec as a key partner in building Saudi Arabia's biotech ecosystem (Key Developments).Narrative Update • Nov 23
603259: New Regional Partnerships And Margin Gains Will Drive Future Performance
Analysts have slightly raised their price target for WuXi AppTec from $124.47 to $125.68. They cite refinements in their valuation models and modest improvements in projected profit margins as the reasons for this adjustment.Narrative Update • Nov 07
603259: Improving Margins and New Partnerships Will Drive Stronger Returns
Narrative Update: WuXi AppTec Price Target Revision Analysts have raised their price target for WuXi AppTec from $118.42 to $124.47. This change reflects improved profit margin expectations and a lower anticipated future price-to-earnings ratio.Narrative Update • Oct 24
Upcoming Meetings and Capital Moves Will Drive Long-Term Opportunities
Analysts have slightly raised their price target for WuXi AppTec to $118.42, up from $117.74. This adjustment reflects modest improvements in projected revenue growth and profit margins.Narrative Update • Oct 10
Global Pharmaceutical R&D Demand Will Unlock Future Value
Analysts have raised their price target for WuXi AppTec from $115.09 to $117.74. They cite slightly improved revenue growth and profit margin expectations, which support a modestly higher valuation.Narrative Update • Sep 26
Global Pharmaceutical R&D Demand Will Unlock Future Value
The consensus analyst price target for WuXi AppTec has remained largely unchanged as a marginally improved revenue growth outlook has been largely offset by a significantly higher future P/E multiple, resulting in only a minor upward adjustment to the fair value estimate. What's in the News WuXi AppTec approved amendments to its Articles of Association, work policies for independent directors, cumulative voting, fund management, connected transactions, external guarantees, financial assistance, and investment management, and proposed the cancellation of its Supervisory Committee along with a change in registered capital.Narrative Update • Aug 25
Aggressive Capacity Expansion Will Magnify Future Overvaluation Risks
The upward revision in WuXi AppTec's consensus Analyst Price Target reflects increased optimism driven by a notable rise in both future P/E and net profit margin, raising the fair value estimate from CN¥106.50 to CN¥112.51. What's in the News Completed HKD 7.70 billion follow-on equity offering, issuing 73.8 million H shares at HKD 104.27 per share through a subsequent direct listing.
New Narrative • May 04
CRDMO And TIDES Segments Will Advance Global Capacity
Strong CRDMO and WuXi TIDES segment growth ensures sustained revenue increases and potential margin improvement through capacity and demand leverage.Shareholder Returns
| 603259 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 17.1% | 15.5% | -2.9% |
| 1Y | 76.1% | 44.8% | 28.3% |
Return vs Industry: 603259 exceeded the CN Life Sciences industry which returned 44.8% over the past year.
Return vs Market: 603259 exceeded the CN Market which returned 28.3% over the past year.
Price Volatility
| 603259 volatility | |
|---|---|
| 603259 Average Weekly Movement | 6.2% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in CN Market | 10.8% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 603259 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603259's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 33,834 | Ge Li | www.wuxiapptec.com |
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic.
WuXi AppTec Co., Ltd. Fundamentals Summary
| 603259 fundamental statistics | |
|---|---|
| Market cap | CN¥374.63b |
| Earnings (TTM) | CN¥18.80b |
| Revenue (TTM) | CN¥46.20b |
19.7x
P/E Ratio8.0x
P/S RatioIs 603259 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603259 income statement (TTM) | |
|---|---|
| Revenue | CN¥46.20b |
| Cost of Revenue | CN¥22.78b |
| Gross Profit | CN¥23.42b |
| Other Expenses | CN¥4.62b |
| Earnings | CN¥18.80b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 04, 2026
| Earnings per share (EPS) | 6.32 |
| Gross Margin | 50.70% |
| Net Profit Margin | 40.69% |
| Debt/Equity Ratio | 9.4% |
How did 603259 perform over the long term?
See historical performance and comparisonDividends
1.5%
Current Dividend Yield30%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/30 16:52 |
| End of Day Share Price | 2026/06/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
WuXi AppTec Co., Ltd. is covered by 43 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Zhishun Siu | CCB International Securities Limited |
| Pei Cheng | China Galaxy Securities Co., Ltd. |